Online inquiry

IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 1, 5-Methyl-CTP, 120 nt-poly(A))   (CAT#: GTTS-WQ12152MR)

This product GTTS-WQ12152MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CD248 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_020404.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57124
UniProt ID Q9HCU0
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD248, MORAb-004(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) (GTTS-WQ12152MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ1196MR IVTScrip™ mRNA-Anti-ERBB2, ABP 980(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA ABP 980
GTTS-WQ10646MR IVTScrip™ mRNA-Anti-S, LY-3819253(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA LY-3819253
GTTS-WQ8750MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ5645MR IVTScrip™ mRNA-Anti-TNF, CDP870(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDP870
GTTS-WQ14768MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SGN-35
GTTS-WQ5093MR IVTScrip™ mRNA-Anti-CSF2RA, CAM-3001(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA CAM-3001
GTTS-WQ358MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ4849MR IVTScrip™ mRNA-Anti-SDC1, BT-062(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BT-062
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW